Alle Fotos(1)

Dokumente

L6668

Lercanidipine -hydrochlorid

Name: Lercanidipine -hydrochlorid
Brand: SIGMA

≥98% (HPLC), powder, dihydropyridine calcium-channel blocker

Synonym(e):

1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester 3,5-pyridinedicarboxylic acid hydrochloride

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise

Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):

C₃₆H₄₁N₃O₆ · HCl

CAS-Nummer:

132866-11-6

Molekulargewicht:

648.19

MDL-Nummer:

MFCD07773089

UNSPSC-Code:

12352200

PubChem Substanz-ID:

24724527

NACRES:

NA.77

product name

Lercanidipine -hydrochlorid, ≥98% (HPLC)

Assay

≥98% (HPLC)

Form

powder

Lagerbedingungen

desiccated
protect from light

Farbe

yellow

Ersteller

Forest Labs

Lagertemp.

2-8°C

SMILES String

O=C(OC)C1=C(C)NC(C)=C(C(OC(C)(C)CN(C)CCC(C2=CC=CC=C2)C3=CC=CC=C3)=O)C1C4=CC([N+]([O-])=O)=CC=C4.Cl

InChI

1S/C36H41N3O6.ClH/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27;/h7-19,22,30,33,37H,20-21,23H2,1-6H3;1H

InChIKey

WMFYOYKPJLRMJI-UHFFFAOYSA-N

Biochem./physiol. Wirkung

Lercanidipine hydrochloride is a L-type (Ca_v1.2b) vascular channel antagonist; L-type (Ca_v1.2a) cardiac channel agonist voltage-dependent and highly lipophylic compound, which exhibits a slower onset and longer duration of action than other calcium channel antagonists; an antihypertensive agent in patients with mild-to-moderate hypertension; more vasoselective than lacidipine and amlodipine.

Leistungsmerkmale und Vorteile

This compound was developed by Forest Labs. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Piktogramme

GHS06

Signalwort

Danger

H-Sätze

H301

P-Sätze

P264 - P270 - P301 + P310 - P405 - P501

Gefahreneinstufungen

Acute Tox. 3 Oral

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 1

1 of 1

Sigma-Aldrich

K1751

Ketoprofen

Determination of pK(a) values of some antihypertensive drugs by liquid chromatography and simultaneous assay of lercanidipine and enalapril in their binary mixtures.

Mehmet Gumustas et al.

Talanta, 82(4), 1528-1537 (2010-08-31)

In this study, pK(a) values were determined using the dependence of the retention factor on the pH of the mobile phase for three ionizable substances, namely, enalapril, lercanidipine and ramipril (IS). The effect of the mobile phase composition on the

Study of cosurfactant effect on nanoemulsifying area and development of lercanidipine loaded (SNEDDS) self nanoemulsifying drug delivery system.

Nitin Parmar et al.

Colloids and surfaces. B, Biointerfaces, 86(2), 327-338 (2011-05-10)

The present study deals with the development and characterization of self-nanoemulsifying drug delivery system (SNEDDS) to improve the oral bioavailability of poorly soluble third generation calcium channel blocker lercanidipine (LER). Solubility of the LER was estimated in various oils, cosurfactants

Management of lercanidipine overdose with hyperinsulinaemic euglycaemia therapy: case report.

George Hadjipavlou et al.

Scandinavian journal of trauma, resuscitation and emergency medicine, 19(1), 8-8 (2011-01-22)

This case report describes the first reported overdose of the dihydropyridine calcium channel blocker (CCB) lercanidipine. A 49 yr old male presented to the Emergency Department 3 hrs after the ingestion of 560 mg of lercanidipine. In the department he

Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice.

Arrigo F G Cicero et al.

Clinical and experimental hypertension (New York, N.Y. : 1993), 34(2), 113-117 (2011-10-05)

The aim of this study is to assess the blood pressure (BP) and metabolic effects of lercanidipine when combined with other classes of first-line antihypertensive drugs in day-to-day clinical practice. For this study, we consecutively enrolled 162 patients with uncomplicated

Incidence and clinical course of lercanidipine-associated cloudy effluent in continuous ambulatory peritoneal dialysis.

P-J Hsiao et al.

Clinical nephrology, 74(3), 217-222 (2010-09-24)

Lercanidipine, a novel dihydropyridine calcium channel antagonist, has been reported to cause sterile cloudy effluent in patients on continuous ambulatory peritoneal dialysis (CAPD). The purpose of the study was to evaluate the incidence and clinical course of cloudy effluent associated

Alle zugehörigen Dokumente anzeigen

Artikel

Calcium Channels

We offers many products related to calcium channels for your research needs.

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.